^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also

Published date:
04/20/2015
Excerpt:
Fluorescent in situ hybridization for CEP17, HER2, and TOP2A was performed in three laboratories on samples from 3,846 of 4,864 eligible patients from five trials evaluating anthracycline-containing chemotherapy versus CMF….Both CEP17and TOP2A treatment-by-marker interactions remained significant in adjusted analyses for recurrence-free and overall survival, whereas HER2 did not....patients whose tumors harbor either CEP17 duplication or TOP2A aberrations, but not HER2 amplification, benefit from adjuvant anthracycline chemotherapy.
DOI:
10.1200/JCO.2013.54.7869